Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers

Incyte announced it will present data from six programs at the ESMO Congress 2026 in Madrid, featuring four rapid oral presentations focused on its solid tumor portfolio. Key presentations include Phase 1 data for KRAS G12D inhibitor INCB161734 in colorectal and pancreatic cancers and TGFβR2×PD-1 bispecific INCA33890 in MSS colorectal cancer, both of which are currently being evaluated in ongoing Phase 3 programs.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.